RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up

Gilead (GILD) Lags Other Biotechs Following HCV Data From Regulus (RGLS)

Gilead Sciences (NASDAQ: GILD) shares declined Wednesday, falling over 1.5% despite gains in the Nasdaq biotech index, which was up 2.75%.

Softness in shares of Gilead follows positive data from Regulus Therapeutics (NASDAQ: RGLS). Earlier Regulus announced... More

FBR Capital Reiterates Outperform Following Regulus Therapeutics' (RGLS) Positive RG-101 Results

FBR Capital reiterated an Outperform rating and $30.00 price target on Regulus Therapeutics (NASDAQ: RGLS) following the company's announcement of positive results from its interim analysis of RG-101 in combination with direct-acting antivirals. In patients evaluated for eight-week follow-up, 97% (37/38) of the patients demonstrated HCV RNA viral load measurements below the limit of quantification. FBR expects additional data at the European Association for the Study of the Liver (EASL) meeting... More

Regulus Therapeutics (RGLS) PT Lifted to $48 at Wedbush

Wedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Regulus Therapeutics (NASDAQ: RGLS) to $48.00 (from $42.00) after interim results suggest with only 29 days treatment RG-101 / DAA treatment combinations were able to reduce HCV viral load to BLOQ in 97% of patients at 8 week follow.

Moussatos commented, "Regulus announced positive interim... More

Needham & Company Reiterates Bullish View on Regulus Therapeutics (RGLS) Following Latest Data

Needham & Company analyst Alan Carr reiterated a Buy rating and $25 price target on Regulus Therapeutics (NASDAQ: RGLS) following positive Phase 2 RG-101 results.

Pts were administered an injection of RG-101, a 4-wk regimen of Harvoni, Olysio, or Daklinza, and then one more injection... More

Regulus Therapeutics (RGLS) Gains Sharply on Encouraging RG-101 Phase 2 Results

Regulus Therapeutics (NASDAQ: RGLS) is up 39.8% in pre-open trading Wednesday after the company... More